Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Contribution of CD4 and CD8 cells to retinal ganglion cell loss in glaucoma
Author Affiliations & Notes
  • Jordan Mayberry
    University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
    US Department of Veterans Affairs, Iowa City, Iowa, United States
  • Huilan Zeng
    University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
    US Department of Veterans Affairs, Iowa City, Iowa, United States
  • Markus H Kuehn
    University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
    US Department of Veterans Affairs, Iowa City, Iowa, United States
  • Footnotes
    Commercial Relationships   Jordan Mayberry None; Huilan Zeng None; Markus Kuehn None
  • Footnotes
    Support  VA Center Grant 1I50RX003002-01 and NIH R01 EY034534
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 572. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jordan Mayberry, Huilan Zeng, Markus H Kuehn; Contribution of CD4 and CD8 cells to retinal ganglion cell loss in glaucoma. Invest. Ophthalmol. Vis. Sci. 2024;65(7):572.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Loss of retinal ganglion cells (RGC) is the ultimate cause of vision loss in glaucoma. Although elevated intraocular pressure (IOP) has been identified as a main risk factor for the development of glaucoma, disease progression is likely due to multiple pathomechanisms. Our previous studies have demonstrated that adoptive transfer of CD3 cells from glaucomatous mice into healthy recipients results in progressive loss of RGC. Conversely, RAG mice lacking T and B cells, are protected from glaucomatous damage caused by elevated IOP. These data indicate that adaptive immune responses are one of the factors leading to vision loss in glaucoma. The current study was conducted in order to determine the functional contribution of CD4 and CD8 T cells in this process.

Methods : Elevated IOP was induced in the eyes of C57Bl/6J controls, Cd4 knockout (KO), and Cd8 KO mice through intracameral injection of Ad5.MyocY437H (n=25/group). IOP was measured weekly using rebound tonometry. Visual acuity was determined monthly by measuring the optokinetic response (OKR). RGC loss was assessed in whole-mounted retinas following immunohistochemical labeling of RGC with antibodies against RBPMS. After 4 months of elevated IOP, spleens were harvested, homogenized, and transferred into RAG recipient mice by intraperitoneal injection.

Results : After 4 months of elevated IOP, the OKR in controls had decreased by 0.097 cycle/degree (c/d), whereas in Cd4 KO OKR had decreased by 0.050 (p=0.03) and by 0.068 c/d in Cd8 KO (p=0.26). RGC density decreased in all groups with elevated IOP (p<0.0009). RAG mice receiving adoptive transfers of splenocytes from these groups also developed RGC damage. 4 months after transplantation, OKR responses in RAG receiving control splenocytes decreased by 0.069 c/d (p=0.032), whereas those that received Cd4 KO or CD8 KO splenocytes decreased by 0.048 c/d (p=0.21) or 0.083 (p=0.009), respectively. RGC density in recipient mice decreased from 3,404 cells/mm2 in naïve RAG mice to 2,865 cells/mm2 in control recipients, 2,938 cells/mm2 in Cd4 KO recipients, and 2,544 cells/mm2 in Cd8 KO recipients. No differences between Cd4 or Cd8 KO were found when compared to controls.

Conclusions : Neither absence of CD4 or CD8 cells resulted in robust RGC protection in donor or recipient mice. This suggests compensatory mechanisms in Cd4 and Cd8 KO mice or that other cell populations contribute stronger to RGC loss than appreciated.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×